• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Predicting the Risk of Graves Disease Relapse: Commentary on "Thyroid Peroxidase Antibody Positivity is Associated with Relapse-Free Survival Following Antithyroid Drug Treatment for Graves Disease".

作者信息

Gallo D, Tanda M L, Piantanida E

机构信息

From the Department of Medicine and Surgery, Endocrine Unit, University of Insubria, Varese, Italy.

From the Department of Medicine and Surgery, Endocrine Unit, University of Insubria, Varese, Italy..

出版信息

Endocr Pract. 2020 Sep;26(9):1039-1041. doi: 10.4158/EP-2020-0230.

DOI:10.4158/EP-2020-0230
PMID:33471693
Abstract
摘要

相似文献

1
Predicting the Risk of Graves Disease Relapse: Commentary on "Thyroid Peroxidase Antibody Positivity is Associated with Relapse-Free Survival Following Antithyroid Drug Treatment for Graves Disease".预测格雷夫斯病复发风险：对“甲状腺过氧化物酶抗体阳性与格雷夫斯病抗甲状腺药物治疗后的无复发生存相关”的评论
Endocr Pract. 2020 Sep;26(9):1039-1041. doi: 10.4158/EP-2020-0230.
2
Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy.甲状腺过氧化物酶和甲状腺球蛋白抗体的变化可能与抗甲状腺药物治疗后 Graves 病的复发有关。
Endocrinol Metab (Seoul). 2019 Sep;34(3):268-274. doi: 10.3803/EnM.2019.34.3.268.
3
Thyroid Peroxidase Antibody Positivity is Associated With Relapse-Free Survival Following Antithyroid Drug Treatment for Graves Disease.甲状腺过氧化物酶抗体阳性与Graves病抗甲状腺药物治疗后的无复发生存相关。
Endocr Pract. 2020 Sep;26(9):1026-1030. doi: 10.4158/EP-2020-0035.
4
Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.采用人促甲状腺激素受体的新型促甲状腺激素结合抑制活性测定法在抗甲状腺药物治疗的格雷夫斯病随访中的临床价值。与促甲状腺激素刺激抗体生物测定法的比较。
Clin Endocrinol (Oxf). 2001 Jan;54(1):89-96. doi: 10.1046/j.1365-2265.2001.01197.x.
5
Valuable predictive features of relapse of Graves' disease after antithyroid drug treatment.抗甲状腺药物治疗后Graves病复发的重要预测特征。
Ann Endocrinol (Paris). 2015 Dec;76(6):679-83. doi: 10.1016/j.ando.2015.08.004. Epub 2015 Oct 27.
6
The Role of Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) Gene, Thyroid Stimulating Hormone Receptor (TSHR) Gene and Regulatory T-cells as Risk Factors for Relapse in Patients with Graves Disease.细胞毒性T淋巴细胞相关蛋白4（CTLA-4）基因、促甲状腺激素受体（TSHR）基因及调节性T细胞作为格雷夫斯病患者复发风险因素的作用
Acta Med Indones. 2017 Jul;49(3):195-204.
7
Thyroid-stimulating hormone receptor antibodies during follow-up as remission markers in childhood-onset Graves' disease treated with antithyroid drugs.随访中甲状腺刺激素受体抗体作为儿童发病格雷夫斯病抗甲状腺药物治疗缓解的标志物。
Kaohsiung J Med Sci. 2020 Apr;36(4):281-286. doi: 10.1002/kjm2.12167. Epub 2019 Dec 18.
8
Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease.抗甲状腺药物可抑制放射性碘诱导的甲状腺功能亢进型格雷夫斯病患者甲状腺自身抗体升高。
Thyroid. 1999 Aug;9(8):775-9. doi: 10.1089/thy.1999.9.775.
9
Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs.甲巯咪唑剂量对格雷夫斯病缓解率有影响吗？一项长期前瞻性研究的结果。欧洲抗甲状腺药物治疗甲状腺功能亢进多中心试验组
Clin Endocrinol (Oxf). 1998 Oct;49(4):451-7. doi: 10.1046/j.1365-2265.1998.00554.x.
10
High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves' disease treated with propylthiouracil.在接受丙硫氧嘧啶治疗的儿童期发病的格雷夫斯病中抗中性粒细胞胞浆抗体阳性的高患病率。
J Clin Endocrinol Metab. 2000 Nov;85(11):4270-3. doi: 10.1210/jcem.85.11.7000.

引用本文的文献

1
[Expression of thyroglobulin antibody and thyroid peroxidase antibody in children with immune thrombocytopenia].[免疫性血小板减少症患儿甲状腺球蛋白抗体和甲状腺过氧化物酶抗体的表达]
Zhongguo Dang Dai Er Ke Za Zhi. 2022 Jun 15;24(6):687-692. doi: 10.7499/j.issn.1008-8830.2112150.